(Q35861269)

10 August 2017

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment (English)

1 reference

juvenile rheumatoid arthritis

10 August 2017

1 reference

3

Jeffrey R Curtis

1 reference

10 August 2017

9

Daniel H Solomon

1 reference

10 August 2017

10

James D Lewis

1 reference

10 August 2017

7

Elizabeth Delzell

1 reference

10 August 2017

8

Kenneth G Saag

1 reference

10 August 2017

1

Timothy Beukelman

1 reference

10 August 2017

Kevin Haynes

2

1 reference

10 August 2017

Fenglong Xie

4

1 reference

10 August 2017

Lang Chen

5

1 reference

10 August 2017

Christina J Bemrich-Stolz

6

1 reference

10 August 2017

Safety Assessment of Biological Therapeutics Collaboration

11

1 reference

10 August 2017

language of work or name

1 reference

10 February 2012

1 reference

10 August 2017

Arthritis & Rheumatology

1 reference

10 August 2017

64

1 reference

10 August 2017

4

1 reference

10 August 2017

1263-1271

1 reference

Malignancies in juvenile idiopathic arthritis: a preliminary report

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Acute lymphoblastic leukemia masquerading as juvenile rheumatoid arthritis: diagnostic pitfall and association with survival.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Under-reporting of adverse drug reactions : a systematic review

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Cancer incidence in a general population of asthma patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

A review of uses of health care utilization databases for epidemiologic research on therapeutics

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

The German etanercept registry for treatment of juvenile idiopathic arthritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Prolonged efficacy of etanercept in refractory enthesitis-related arthritis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3315602

Hodgkin's lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report

24 September 2018

1 reference

12 December 2020

Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis?

1 reference

12 December 2020

Risk of malignancy among patients with rheumatic conditions

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Quality of care for patients with rheumatoid arthritis

1 reference

12 December 2020

Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis

1 reference

12 December 2020

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

1 reference

12 December 2020

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

12 December 2020

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

1 reference

12 December 2020

Identifiers

DOI

10.1002/ART.34348

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22328538

1 reference